Increased eosinophil counts have been recognised to be linked to asthma severity and are a risk factor for asthma exacerbations. Therefore, decreasing eosinophil count by targeting the interleukin-5-mediated signalling pathway could help to reduce airway inflammation and improve asthma treatment control. In The Lancet Respiratory Medicine, Mario Castro and colleagues1 report data from two large, randomised, placebo-controlled trials, in which reslizumab, a neutralising monoclonal antibody for interleukin 5, was safe and effective in patients with severe eosinophilic asthma.
Recent Posts
- Can measures of small airway dysfunction aid with the diagnosis or management of asthma exacerbations? A systematic review
- Risk factors for asthma exacerbations
- Single-cell profiling demonstrates the combined effect of wheeze phenotype and infant viral infection on airway epithelial development
- Evaluation of recently proposed thresholds to define spirometry bronchodilator response
- Burden of disease and unmet clinical needs in pediatric patients with asthma: real-world experience from the United States and five European countries